ESC 2023 Brand Buzz

Online analysis based on ESC 2023 mentions
in the period 17 August 2023 – 03 September 2023

25-28 AUG

2023

The European Society of Cardiology Congress (ESC) 2023 returned to Amsterdam with the theme “Joining forces to protect the heart”, serving as a nexus for medical professionals to collaborate and enrich their knowledge. This year’s spotlight was on the rapidly evolving field of heart failure, with a comprehensive program that covered the full spectrum of cardiology. Nearly 3,500 abstracts were presented by 3,000 investigators from 86 countries, and the congress featured a new Clinical Implementation Track to help healthcare professionals apply the latest research in practice.

Activity Over Time

Volume over time is tracked back to one month before the event when most exhibitors started announcing their participation.

Key Event Topics

* Relative shares are calculated out of all categorised posts within the respective social media. Posts about the leading 5 topics are 63% of all categorised posts.

**In Twitter only, New Product Release ranked higher than Partnerships.

Competitive Brand Buzz

The top brands that have generated the most engagement with their social media activity – likes, comments, reshares, etc

Brands Strategies & Key Topic Comparison

What did the highest ranking companies in the Brand Buzz analysis talk about?

GE HealthCare focused on product launches, customer engagement, and thought leadership in the cardiology space. They unveiled two key products, Vscan Air SL and CardioVisio for AFib, aimed at rapid cardiac assessments and decision support, respectively. They emphasized the importance of these innovations in addressing the challenges of cardiovascular disease, showcased their commitment to customer-centric solutions, and highlighted their collaborations with industry experts to improve cardiac care.

Novo Nordisk’s communication strategy focused on thought leadership, research, and the interconnectedness of cardiovascular disease with other conditions like diabetes and obesity. The company highlighted discussions with medical experts on the importance of proactive treatment and education, emphasizing their commitment to driving change through science, data, and innovation. The company also celebrated their 100th anniversary to underscore their long-term commitment to healthcare.

Abbott’s announcements centered on showcasing groundbreaking clinical data, particularly from their ILUMIEN IV study, to emphasize the role of intravascular imaging in improving patient outcomes for complex coronary diseases. The company also offered hands-on tutorials and symposiums led by experts, aiming to educate attendees on the latest innovations in cardiac rhythm management and percutaneous coronary intervention (PCI). Abbott highlighted the collaborative efforts of their team and investigators, inviting the community to review their data and join discussions, thereby positioning themselves as a leader in cardiovascular solutions.